Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.

ABSTRACT:

Objective

Persistent immune activation is thought to contribute to increased cardiovascular disease risk in HIV and statins may help modulate systemic immune activation. We aimed to compare the effects of two key statins on markers of systemic immune activation and arterial inflammation in the HIV population.

Design

Double-blind, active-controlled, parallel-group comparative trial performed in 45 sites.

Methods

Two hundred and fifty-two antiretroviral therapy-treated HIV-infected participants with dyslipidemia were randomized (1 : 1) to pitavastatin 4 mg daily vs. pravastatin 40 mg daily in the HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia (INTREPID) trial. In this analysis of the INTREPID trial, we assessed markers of immune a

SUBMITTER: Toribio M 

PROVIDER: S-EPMC5382495 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature